Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has provided an update.
CR Sanjiu reported its unaudited financial results for the nine months ending September 30, 2025, showing a revenue increase to RMB 21.99 billion from RMB 19.74 billion in the previous year, despite a decline in net profit to RMB 2.90 billion from RMB 3.24 billion. The financials highlight a net decrease in cash and cash equivalents and a significant rise in total assets and liabilities, indicating potential adjustments during auditing, and advising caution for shareholders and investors.
The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
More about China Resources Pharmaceutical Group Ltd.
China Resources Sanjiu Medical & Pharmaceutical Company Limited (CR Sanjiu) is a subsidiary of China Resources Pharmaceutical Group Limited, operating in the pharmaceutical industry. The company is listed on the Shenzhen Stock Exchange and primarily focuses on medical and pharmaceutical products.
Average Trading Volume: 16,744,630
Technical Sentiment Signal: Sell
Current Market Cap: HK$30.6B
See more data about 3320 stock on TipRanks’ Stock Analysis page.